Streetbeat News

Earnings

ACOR

ENVB

GLYC

IMNN

ONMD

In Tuesday's after-market session, several health care stocks showed significant movement. OneMedNet (ONMD) led the gainers with a 75.9% increase, while Enveric Biosciences (ENVB) experienced the largest drop among the losers, decreasing by 14.1%. Notably, companies like GlycoMimetics (GLYC), Acorda Therapeutics (ACOR), and Imunon (IMNN) had recent earnings reports influencing their stock movements.

Portfolio Pulse from Benzinga Insights

April 02, 2024 | 8:31 pm

MVST

PEGY

SRFM

VLD

VLRS

ZCAR

In Tuesday's after-market session, several industrials stocks saw movements. Pineapple Energy, Surf Air Mobility, and Microvast Holdings were among the gainers with their stocks increasing due to recent Q4 earnings reports. Conversely, Velo3D, Zoomcar Holdings, and Controladora Vuela were among the losers. The movements reflect the market's reaction to the latest earnings and company valuations.

Portfolio Pulse from Benzinga Insights

April 02, 2024 | 8:31 pm

DTST

INTZ

OMQS

In Tuesday's after-market session, 12 Information Technology stocks showed notable movements. OMNIQ, Expensify, Maxeon Solar Technologies, BitFuFu, Spectaire Holdings, and Wetouch Technology were gainers, with OMNIQ leading at a 7.7% increase following its Q4 earnings release. On the downside, Intrusion, Data Storage, UTime, CISO Global, Cyngn, and GSE Systems experienced declines, with Intrusion dropping 5.3%. Notably, both Data Storage and GSE Systems had their Q4 earnings released recently.

Portfolio Pulse from Benzinga Insights

April 02, 2024 | 8:30 pm

INNPF

Innocan Pharma Corporation reported a 534% revenue increase for the year ended December 31, 2023, reaching US$13.7 million, primarily due to its subsidiary, BI Sky Global Ltd. The company also saw a 61% decrease in operating loss to US$3.8 million and a 568% increase in gross profit to US$12.0 million. Additionally, Innocan completed a $1.5 million capital raise in March 2024 and is pursuing FDA approval for its LPT CBD-loaded liposome platform.

Portfolio Pulse from Patricio Liddle

April 02, 2024 | 8:28 pm

VEV

Vicinity Motor Corp. (VEV) reported a Q4 EPS loss of $(0.20), widening from a $(0.08) loss per share last year. Sales surged to $5.10M, marking a 155% increase from $2.0M in the same period last year.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 8:25 pm

PLAY

Dave & Buster's Enter (NASDAQ:PLAY) reported Q4 earnings with a -6.0% miss on estimated earnings, posting an EPS of $1.03 against an estimate of $1.1. Revenue increased by $35.34 million from the same period last year. Despite missing EPS estimates last quarter, the share price increased by 4.0% the following day. Historical earnings performance shows mixed results over the past quarters.

Portfolio Pulse from Benzinga Insights

April 02, 2024 | 8:25 pm

CALM

Cal-Maine Foods (NASDAQ:CALM) reported Q3 earnings with an EPS of $3.0, beating estimates by 22.0% but with a revenue decrease from the previous year. Despite missing EPS estimates last quarter, the share price increased by 3.0% the following day.

Portfolio Pulse from Benzinga Insights

April 02, 2024 | 8:25 pm

INTC

Intel aims to achieve 60% non-GAAP gross margins and 40% non-GAAP operating margins by 2030 through significant cost savings, operational efficiencies, and asset value optimization, as stated by CFO Dave Zinsner. This strategy is expected to enhance Intel's cost competitiveness and drive financial growth.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 8:15 pm

SGHT

Sight Sciences, Inc. (NASDAQ:SGHT) announced the presentation of clinical results for its OMNI Surgical System and TearCare System at the 2024 ASCRS Annual Meeting. The OMNI technology showed long-term efficacy in treating primary open-angle glaucoma, while the TearCare technology was supported as a primary treatment for dry eye disease. The data includes results from the 3-year GEMINI trial and the cross-over phase of the SAHARA RCT, demonstrating the effectiveness of these technologies in improving patient outcomes.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 8:13 pm

ADPT

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) announced a strategic review update, preliminary Q1 2024 revenue of $41M-$43M, exceeding estimates of $38.21M, and a CFO transition. The review concluded with a decision to operate the MRD and Immune Medicine businesses internally with increased independence and dedicated resources. MRD revenue for Q1 2024 is expected to be $31M-$32M, a 47% increase from Q1 2023. Tycho Peterson will depart as CFO, succeeded by Kyle Piskel.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 8:12 pm